Close affiliation

A fresh investment in antibody manufacturing capacity in China will enable both Seattle-based Just Biotherapeutics Inc. and its affiliate Hangzhou Just Biotherapeutics Ltd. to scale up for late stage trials and commercial launches.

The U.S. company, which holds an undisclosed stake in the Hangzhou affiliate, has technology for low-cost antibody production, as well as a pilot GMP manufacturing plant and an undisclosed pipeline...